By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...